Yissum, the tech transfer office (TTO) of Hebrew University, appointed Yaron Daniely (pictured), as its chief executive this month.

Daniely, who stepped down as CEO at cognitive therapeutics developer Alcobra on May 31, but then became the company’s chairman, had spent seven years in that post.

His resume includes stints at other Israel-based pharmaceuticals developers, including as director at Bioblast from 2012 to 2014, and as chief executive of Nanocyte Medical between 2007 and 2010.

Yissum has secured more than…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?